NCT00129571

Brief Summary

The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2005

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 12, 2005

Completed
Last Updated

June 4, 2008

Status Verified

June 1, 2008

First QC Date

August 10, 2005

Last Update Submit

June 2, 2008

Conditions

Cancer

Interventions

XL820DRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Advanced solid tumor
  • Cancer for which standard therapies do not exist or are no longer effective
  • Life expectancy of \> 3 months
  • Adequate bone marrow, liver, and kidney function
  • Willing to use accepted method of contraception during the course of the study
  • Negative pregnancy test (females)
  • Written informed consent

You may not qualify if:

  • Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
  • Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
  • Investigational drug within 30 days of the start of treatment
  • Subjects with known brain metastasis
  • Uncontrolled medical disorder such as infection or cardiovascular disease
  • Subjects known to be HIV positive
  • Pregnant or breastfeeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

The Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States

Location

Cancer Therapy and Research Center

San Antonio, Texas, 78229, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

August 10, 2005

First Posted

August 12, 2005

Study Start

August 1, 2005

Last Updated

June 4, 2008

Record last verified: 2008-06

Locations

US(2)